Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 30


Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck.

Mix M, Singh AK, Tills M, Dibaj S, Groman A, Jaggernauth W, Rustum Y, Jameson MB.

World J Clin Oncol. 2015 Oct 10;6(5):166-73. doi: 10.5306/wjco.v6.i5.166.


Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer.

Mix M, Ramnath N, Gomez J, de Groot C, Rajan S, Dibaj S, Tan W, Rustum Y, Jameson MB, Singh AK.

World J Clin Oncol. 2015 Oct 10;6(5):156-65. doi: 10.5306/wjco.v6.i5.156.


Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O'Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP.

Clin Genitourin Cancer. 2015 Feb;13(1):50-8. doi: 10.1016/j.clgc.2014.07.002. Epub 2014 Jul 15.


Adding selenium to chemotherapy and radiation in haematological malignancies: clinical trials are justified.

Jameson MB, Evans SO.

Acta Haematol. 2014;132(2):254-5. No abstract available.


Review of high-dose intravenous vitamin C as an anticancer agent.

Wilson MK, Baguley BC, Wall C, Jameson MB, Findlay MP.

Asia Pac J Clin Oncol. 2014 Mar;10(1):22-37. doi: 10.1111/ajco.12173. Review.


Prognostic molecular markers in head and neck squamous cell carcinoma in a New Zealand population: matrix metalloproteinase-2 and sialyl Lewis x antigen.

Gunawardena I, Arendse M, Jameson MB, Plank LD, Gregor RT.

ANZ J Surg. 2015 Nov;85(11):843-8. doi: 10.1111/ans.12424. Epub 2013 Oct 31.


A randomized pilot trial of dietary modification for the chemoprevention of noninvasive bladder cancer: the dietary intervention in bladder cancer study.

Parsons JK, Pierce JP, Natarajan L, Newman VA, Barbier L, Mohler J, Rock CL, Heath DD, Guru K, Jameson MB, Li H, Mirheydar H, Holmes MA, Marshall J.

Cancer Prev Res (Phila). 2013 Sep;6(9):971-8. doi: 10.1158/1940-6207.CAPR-13-0050. Epub 2013 Jul 18. Erratum in: Cancer Prev Res (Phila). 2013 Dec;6(12):1378.


A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.

Harvey VJ, Sharples KJ, Isaacs RJ, Jameson MB, Jeffery GM, McLaren BR, Pollard S, Riley GA, Simpson AB, Hinder VA, Scott JN, Dzhelali MV, Findlay MP.

Ann Oncol. 2013 Jul;24(7):1828-34. doi: 10.1093/annonc/mdt065. Epub 2013 Mar 4.


PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.

McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, Melink TJ, Tchekmedyian NS.

BMC Cancer. 2012 Oct 25;12:496. doi: 10.1186/1471-2407-12-496.


Persistent neck disease after chemoradiation for head and neck squamous cell carcinoma.

Sanders JG, Smith KG, Jameson MB, de Groot C, White J.

J Laryngol Otol. 2012 Nov;126(11):1121-6. doi: 10.1017/S0022215112002009. Epub 2012 Sep 19.


Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.

McKeage MJ, Jameson MB; AS1404-201 Study Group Investigators.

J Thorac Dis. 2010 Dec;2(4):199-204. doi: 10.3978/j.issn.2072-1439.2010.02.04.1.


A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.

McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, Jameson MB.

BMC Cancer. 2011 Oct 7;11:432. doi: 10.1186/1471-2407-11-432.


Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).

Jameson MB, Head M.

Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1315-26. doi: 10.1517/17425255.2011.614389. Epub 2011 Aug 26. Review.


A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.

Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, Acton G, Erlandsson F, Spicer JF.

Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. doi: 10.1158/1078-0432.CCR-10-2490. Epub 2011 Mar 29.


The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.

Head M, Jameson MB.

Expert Opin Investig Drugs. 2010 Feb;19(2):295-304. doi: 10.1517/13543780903540214.


A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR.

Cancer Chemother Pharmacol. 2010 Mar;65(4):791-801. doi: 10.1007/s00280-009-1188-1. Epub 2009 Dec 10.


Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J.

Lung Cancer. 2009 Aug;65(2):192-7. doi: 10.1016/j.lungcan.2009.03.027. Epub 2009 May 5.


Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

Jameson MB, Sharp DM, Sissingh JI, Hogg CR, Thompson PI, McKeage MJ, Jeffery M, Waller S, Acton G, Green C, Baguley BC.

Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2553-9. doi: 10.1167/iovs.08-2068. Epub 2009 Apr 22.


Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E.

Br J Cancer. 2008 Dec 16;99(12):2006-12. doi: 10.1038/sj.bjc.6604808.


Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.

Li J, Jameson MB, Baguley BC, Pili R, Baker SD.

Clin Cancer Res. 2008 Apr 1;14(7):2102-10. doi: 10.1158/1078-0432.CCR-07-1475.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk